A bill to amend the Public Health Service Act to direct the Secretary of Health and Human Services to establish, promote, and support a comprehensive prevention, research, and medical management referral program for hepatitis C virus infection.

Summary: Hepatitis C Epidemic Control and Prevention Act - Amends the Public Health Service Act to direct the Secretary of Health and Human Services to develop and implement a plan for the prevention, control, and management of hepatitis C virus (HCV), which shall include strategies for education and training, surveillance and early detection, and research. Requires the Secretary to conduct a biennial assessment of the plan.Directs the Secretary to support the development of voluntary State, local, and tribal HCV testing programs and counseling. Provides for the vaccination of individuals infected with HCV against hepatitis A and B and other infectious diseases.Directs the Secretary to support the establishment and maintenance of HCV surveillance databases and to establish and support a Hepatitis C Clinical Research Network.Allows the Secretary to award grants to States, political subdivisions of States, Indian tribes, or non-profit entities that have special expertise relating to HCV, to carry out activities under this Act.Directs the Director of the National Institutes of Health to establish a Liver Disease Research Advisory Board.

SECTION 1. SHORT TITLE.

    This Act may be cited as the ``Hepatitis C Epidemic Control and 
Prevention Act''.

SEC. 2. FINDINGS.

    Congress makes the following findings:
            (1) Over 3,000,000 individuals in the United States are 
        chronically infected with the hepatitis C virus (referred to in 
        this section as ``HCV''), making it the Nation's most common 
        blood borne virus infection.
            (2) Nearly 2 percent of the population of the United States 
        have been infected with HCV.
            (3) Conservative estimates indicate that approximately 
        35,000 Americans are newly infected with HCV each year.
            (4) HCV infection can cause life-threatening liver disease.
            (5) Individuals infected with HCV serve as a source of 
        transmission to others and, since few individuals are aware 
        they are infected, are unlikely to take precautions to prevent 
        the spread or exacerbation of their infection.
            (6) There is no vaccine available to prevent HCV infection.
            (7) Treatments are available to slow the progression of 
        chronic hepatitis C.
            (8) An estimated 2,400,000 to 2,700,000 people who are 
        chronically infected with hepatitis C are receiving no 
        treatment.
            (9) Conservative estimates place the costs of lost 
        productivity and medical care arising from chronic hepatitis C 
        in the United States at more than $600,000,000 annually and 
        such costs will undoubtedly increase in the absence of expanded 
        prevention and treatment efforts.
            (10) To combat the HCV epidemic in the United States, the 
        Centers for Disease Control and Prevention developed 
        Recommendations for Prevention and Control of Hepatitis C Virus 
        (HCV) Infection and HCV-Related Chronic Disease in 1998 and the 
        National Hepatitis C Prevention Strategy in 2001, and the 
        National Institutes of Health convened Consensus Development 
        Conferences on the Management of Hepatitis C in 1997 and 2002. 
        These recommendations and guidelines provide a framework for 
        hepatitis C prevention, control, research, and medical 
        management referral programs.
            (11) Federal support is necessary to increase knowledge and 
        awareness of hepatitis C and to assist State and local 
        prevention and control efforts.

SEC. 3. PREVENTION, CONTROL, AND MEDICAL MANAGEMENT OF HEPATITIS C.

    Title III of the Public Health Service Act (42 U.S.C. 241 et seq.) 
is amended by adding at the end the following:

  ``PART R--PREVENTION, CONTROL, AND MEDICAL MANAGEMENT OF HEPATITIS C

``SEC. 399AA. FEDERAL PLAN FOR THE PREVENTION, CONTROL, AND MEDICAL 
              MANAGEMENT OF HEPATITIS C.

    ``(a) In General.--The Secretary shall develop and implement a plan 
for the prevention, control, and medical management of hepatitis C 
which includes strategies for education and training, surveillance and 
early detection, and research.
    ``(b) Input in Development of Plan.--In developing the plan under 
subsection (a), the Secretary shall--
            ``(1) be guided by existing recommendations of the Centers 
        for Disease Control and Prevention and the National Institutes 
        of Health; and
            ``(2) consult with--
                    ``(A) the Director of the Centers for Disease 
                Control and Prevention;
                    ``(B) the Director of the National Institutes of 
                Health;
                    ``(C) the Director of the Health Resources and 
                Services Administration;
                    ``(D) the heads of other Federal agencies or 
                offices providing services to individuals with 
                hepatitis C virus (referred to in this part as `HCV') 
                infections or the functions of which otherwise involve 
                hepatitis C;
                    ``(E) medical advisory bodies that address issues 
                related to HCV; and
                    ``(F) the public, including--
                            ``(i) individuals infected with the HCV; 
                        and
                            ``(ii) advocates concerned with issues 
                        related to HCV.
    ``(c) Biennial Update of Plan.--
            ``(1) In general.--The Secretary shall conduct a biennial 
        assessment of the plan developed under subsection (a) for the 
        purpose of incorporating into such plan new knowledge or 
        observations relating to HCV and chronic HCV (such as knowledge 
        and observations that may be derived from clinical, laboratory, 
        and epidemiological research and disease detection, prevention, 
        and surveillance outcomes) and addressing gaps in the coverage 
        or effectiveness of the plan.
            ``(2) Publication of notice of assessments.--Not later than 
        October 1 of the first even numbered year beginning after the 
        date of enactment of this part, and October 1 of each even 
        numbered year thereafter, the Secretary shall publish in the 
        Federal Register a notice of the results of the assessments 
        conducted under paragraph (1). Such notice shall include--
                    ``(A) a description of any revisions to the plan 
                developed under subsection (a) as a result of the 
                assessment;
                    ``(B) an explanation of the basis for any such 
                revisions, including the ways in which such revisions 
                can reasonably be expected to further promote the 
                original goals and objectives of the plan; and
                    ``(C) in the case of a determination by the 
                Secretary that the plan does not need revision, an 
                explanation of the basis for such determination.

``SEC. 399BB. ELEMENTS OF THE FEDERAL PLAN FOR THE PREVENTION, CONTROL, 
              AND MEDICAL MANAGEMENT OF HEPATITIS C.

    ``(a) Education and Training.--The Secretary, acting through the 
Director of the Centers for Disease Control and Prevention, shall 
implement programs to increase awareness and enhance knowledge and 
understanding of hepatitis C. Such programs shall include--
            ``(1) the conduct of health education, public awareness 
        campaigns, and community outreach activities to promote public 
        awareness and knowledge about risk factors, the transmission 
        and prevention of infection with HCV, the value of screening 
        for the early detection of HCV infection, and options available 
        for the treatment of chronic hepatitis C;
            ``(2) the training of health care professionals regarding 
        the prevention, detection, and medical management of hepatitis 
        B and hepatitis C, and the importance of vaccinating HCV-
        infected individuals and those at risk for HCV infection 
        against the hepatitis A virus and hepatitis B virus (referred 
        to in this part as `HBV'); and
            ``(3) the development and distribution of curricula 
        (including information relating to the special needs of 
        individuals infected with HBV or HCV, such as the importance of 
        early intervention and treatment and the recognition of 
        psychosocial needs) for individuals providing hepatitis 
        counseling, as well as support for the implementation of such 
        curricula by State and local public health agencies.
    ``(b) Early Detection and Surveillance.--
            ``(1) In general.--The Secretary, acting through the 
        Director of the Centers for Disease Control and Prevention, 
        shall support activities described in paragraph (2) to promote 
        the early detection of HCV infection, identify risk factors for 
        infection, and conduct surveillance of HCV infection trends.
            ``(2) Activities.--
                    ``(A) Voluntary testing programs.--
                            ``(i) In general.--The Secretary shall 
                        support and promote the development of State, 
                        local, and tribal voluntary hepatitis C testing 
                        programs to aid in the early identification of 
                        infected individuals.
                            ``(ii) Confidentiality of test results.--
                        The results of a hepatitis C test conducted by 
                        a testing program developed or supported under 
                        this subparagraph shall be considered protected 
                        health information (in a manner consistent with 
                        regulations promulgated under section 264(c) of 
                        the Health Insurance Portability and 
                        Accountability Act of 1996 (42 U.S.C. 1320d-
2 note)) and may not be used for any of the following:
                                    ``(I) Issues relating to health 
                                insurance.
                                    ``(II) To screen or determine 
                                suitability for employment.
                                    ``(III) To discharge a person from 
                                employment.
                    ``(B) Counseling regarding viral hepatitis.--The 
                Secretary shall support State, local, and tribal 
                programs in a wide variety of settings, including those 
                providing primary and specialty health care services in 
                the private and the public sectors, to--
                            ``(i) provide individuals with information 
                        about ongoing risk factors for hepatitis C 
                        virus infection with client-centered education 
                        and counseling which concentrates on changing 
                        behaviors that place them at risk for 
                        infection; and
                            ``(ii) provide individuals infected with 
                        hepatitis C virus with education and counseling 
                        to reduce the risk of harm to themselves and 
                        transmission of the virus to others.
                    ``(C) Vaccination against viral hepatitis.--With 
                respect to individuals infected, or at risk for 
                infection, with HCV, the Secretary shall provide for--
                            ``(i) the vaccination of such individuals 
                        against hepatitis A virus, HBV, and other 
                        infectious diseases, as appropriate, for which 
                        such individuals may be at increased risk; and
                            ``(ii) the counseling of such individuals 
                        regarding hepatitis A, hepatitis B, and other 
                        viral hepatides.
                    ``(D) Medical referral.--The Secretary shall 
                support--
                            ``(i) referral of persons infected with or 
                        at risk for HCV, for drug or alcohol abuse 
                        treatment where appropriate; and
                            ``(ii) referral of persons infected with 
                        HCV--
                                    ``(I) for medical evaluation to 
                                determine their stage of chronic 
                                hepatitis C and suitability for 
                                antiviral treatment; and
                                    ``(II) for ongoing medical 
                                management of hepatitis C.
            ``(3) Hepatitis c coordinators.--The Secretary, acting 
        through the Director of the Centers for Disease Control and 
        Prevention, shall, upon request, provide a Hepatitis C 
        Coordinator to a State health department in order to enhance 
        the additional management, networking, and technical expertise 
        needed to ensure successful integration of hepatitis C 
        prevention and control activities into existing public health 
        programs.
    ``(c) Surveillance and Epidemiology.--
            ``(1) In general.--The Secretary shall promote and support 
        the establishment and maintenance of State HCV surveillance 
        databases, in order to--
                    ``(A) identify risk factors for HCV infection;
                    ``(B) identify trends in the incidence of acute and 
                chronic HCV;
                    ``(C) identify trends in the prevalence of HCV 
                infection among groups that may be disproportionately 
                affected by hepatitis C, including individuals living 
                with HIV, military veterans, emergency first 
                responders, racial or ethnic minorities, and 
                individuals who engage in high risk behaviors, such as 
                intravenous drug use; and
                    ``(D) assess and improve HCV infection prevention 
                programs.
            ``(2) Seroprevalence studies.--The Secretary shall conduct 
        a population-based seroprevalence study to estimate the current 
        and future impact of hepatitis C. Such studies shall consider 
        the economic and clinical impacts of hepatitis C, as well as 
        the impact of hepatitis C on quality of life.
            ``(3) Confidentiality.--Information contained in the 
        databases under paragraph (1) or derived through studies under 
        paragraph (2) shall be de-identified in a manner consistent 
        with regulations under section 264(c) of the Health Insurance 
        Portability and Accountability Act of 1996.
    ``(d) Research Network.--The Secretary, acting through the Director 
of the Centers for Disease Control and Prevention and the Director of 
the National Institutes of Health, shall--
            ``(1) conduct epidemiologic research to identify best 
        practices for HCV prevention;
            ``(2) establish and support a Hepatitis C Clinical Research 
        Network for the purpose of conducting research related to the 
treatment and medical management of hepatitis C; and
            ``(3) conduct basic research to identify new approaches to 
        prevention (such as vaccines) and treatment for HCV.
    ``(e) Referral for Medical Management of Chronic Hepatitis C.--The 
Secretary shall support and promote State, local, and tribal programs 
to provide HCV-positive individuals with referral for medical 
evaluation and management, including currently recommended antiviral 
therapy when appropriate.
    ``(f) Underserved and Disproportionately Affected Populations.--In 
carrying out this section, the Secretary shall provide expanded support 
for individuals with limited access to health education, testing, and 
health care services and groups that may be disproportionately affected 
by hepatitis C.
    ``(g) Evaluation of Program.--The Secretary shall develop 
benchmarks for evaluating the effectiveness of the programs and 
activities conducted under this section and make determinations as to 
whether such benchmarks have been achieved.

``SEC. 399CC. GRANTS.

    ``(a) In General.--The Secretary may award grants to, or enter into 
contracts or cooperative agreements with, States, political 
subdivisions of States, Indian tribes, or non-profit entities that have 
special expertise relating to HCV, to carry out activities under this 
part.
    ``(b) Application.--To be eligible for a grant, contract, or 
cooperative agreement under subsection (a), an entity shall prepare and 
submit to the Secretary an application at such time, in such manner, 
and containing such information as the Secretary may require.

``SEC. 399DD. AUTHORIZATION OF APPROPRIATIONS.

    ``There are authorized to be appropriated to carry out this part 
$90,000,000 for fiscal year 2004, and such sums as may be necessary for 
each of fiscal years 2005 through 2008.''.

SEC. 4. LIVER DISEASE RESEARCH ADVISORY BOARD.

    Part A of title IV of the Public Health Service Act (42 U.S.C. 281 
et seq.) is amended by adding at the end the following:

``SEC. 409J. LIVER DISEASE RESEARCH ADVISORY BOARD.

    ``(a) Establishment.--Not later than 90 days after the date of 
enactment of this section, the Director of the National Institutes of 
Health shall establish a board to be known as the Liver Disease 
Research Advisory Board (referred to in this section as the `Advisory 
Board').
    ``(b) Duties.--The Advisory Board shall advise and assist the 
Director of the Centers for Disease Control and Prevention concerning 
matters relating to liver disease research, including by developing and 
revising the Liver Disease Research Action Plan.
    ``(c) Voting Members.--The Advisory Board shall be composed of 18 
voting members to be appointed by the Director of the National 
Institutes of Health, in consultation with the Director of the 
Institute of Allergy and Infectious Diseases, of whom 12 such 
individuals shall be eminent scientists and 6 such individuals shall be 
lay persons. The Director of the National Institutes of Health, in 
consultation with the Director of the Institute, shall select 1 of the 
members to serve as the Chair of the Advisory Board.
    ``(d) Ex Officio Members.--The Director of the National Institutes 
of Health shall appoint each director of a national research institute 
that funds liver disease research to serve as a nonvoting, ex officio 
member of the Advisory Board. The Director of the National Institutes 
of Health shall invite 1 representative of the Centers for Disease 
Control and Prevention, 1 representative of the Food and Drug 
Administration, and 1 representative of the Department of Veterans 
Affairs to serve as such a member. Each ex officio member of the 
Advisory Board may appoint an individual to serve as that member's 
representative on the Advisory Board.
    ``(e) Liver Disease Research Action Plan.--
            ``(1) Development.--Not later than 15 months after the date 
        of the enactment of this section, the Advisory Board shall 
        develop (with appropriate support from the Director and staff 
        of the Center) a comprehensive plan for the conduct and support 
        of liver disease research to be known as the Liver Disease 
        Research Action Plan. The Advisory Board shall submit the Plan 
        to the Director of NIH and the head of each institute or center 
        within the National Institutes of Health that funds liver 
        disease research.
            ``(2) Content.--The Liver Disease Research Action Plan 
        shall identify scientific opportunities and priorities of liver 
        disease research necessary to increase understanding of and to 
        prevent, cure, and develop better treatment protocols for liver 
        diseases.
            ``(3) Revision.--The Advisory Board shall revise every 3 
        years the Liver Disease Research Action Plan, but shall meet 
        annually to review progress and to amend the Plan as may be 
        appropriate because of new scientific discoveries.''.